Eli Lilly to Eliminate 3,500 Jobs; Close Shanghai, N.J. R&D Operations

07:22 EDT 7 Sep 2017 | Genetic Engineering News

Eli Lilly said this morning it will eliminate 8% of its workforce—approximately 3,500 jobs—through a restructuring designed to cut costs and further focus the company on developing new treatments. Lilly said the majority of the 3,500 jobs would be eliminated through a voluntary early retirement program in the U.S., though the company will also shut or consolidate some of its facilities, and eliminate some jobs worldwide. The pharma giant said its global “productivity improvement efforts” will include: The shutdown of its R&D office in Bridgewater, NJ; The shutdown of the Lilly China Research and Development Center in Shanghai; A shift of production from its animal health manufacturing facility in Larchwood, Iowa, to an existing plant in Fort Dodge, Iowa, and Additional consolidations of existing shared service centers. Lilly employed approximately 41,975 people worldwide as ...

Original Article: Eli Lilly to Eliminate 3,500 Jobs; Close Shanghai, N.J. R&D Operations


More From BioPortfolio on "Eli Lilly to Eliminate 3,500 Jobs; Close Shanghai, N.J. R&D Operations"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Eli Lilly and Company was founded in 1876, and is now the 9th largest pharmaceutical company based an annual sales which were just under $20bn in 2009. Orginally from the USA, Lilly now operates in over 50 countries with just under 40,000 employees. Appr...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...